Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1L1 | Q9UHC9 | 5/20 | 0.61 |
| ▸ | USP2 | O75604 | 3/20 | 0.61 |
| ▸ | RORA | P35398 | 3/20 | 0.61 |
| ▸ | MEN1 | O00255 | 2/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.61 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.61 |
| ▸ | CDC25A | P30304 | 5/20 | 0.60 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | RORC | P51449 | 3/20 | 0.55 |
| ▸ | GPR183 | P32249 | 1/20 | 0.55 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.55 |
| ▸ | OSBP | P22059 | 1/20 | 0.55 |
| ▸ | OSBP2 | Q969R2 | 1/20 | 0.55 |
| ▸ | CYP46A1 | Q9Y6A2 | 1/20 | 0.55 |
| ▸ | CDC25B | P30305 | 2/20 | 0.51 |
| ▸ | FNTA | P49354 | 2/20 | 0.48 |
| ▸ | FNTB | P49356 | 2/20 | 0.48 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.47 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.47 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30650227 | 1.00 | NPC1L1 (0.61) | NPC1L1USP2RORAMEN1KMT2A | |
| SCHEMBL13521611 | 1.00 | NPC1L1 (0.61) | NPC1L1USP2RORAMEN1KMT2A | |
| SCHEMBL3138543 | 1.00 | NPC1L1 (0.61) | NPC1L1USP2RORAMEN1KMT2A | |
| SCHEMBL13521658 | 0.89 | CDC25A (0.48) | NPC1L1USP2RORAMEN1KMT2A | |
| SCHEMBL13521609 | 0.89 | CDC25A (0.76) | NPC1L1USP2RORAMEN1KMT2A | |
| SCHEMBL13521653 | 0.88 | NR1H4 (0.52) | NPC1L1USP2RORAMEN1KMT2A | |
| SCHEMBL13521621 | 0.88 | EPHA2 (0.58) | USP2MEN1KMT2ACDC25ALMNA | |
| SCHEMBL14611855 | 0.86 | NR1H4 (0.52) | NPC1L1USP2RORAMEN1KMT2A | |
| SCHEMBL14612021 | 0.85 | CDC25A (0.43) | NPC1L1USP2RORAMEN1KMT2A | |
| SCHEMBL13630375 | 0.80 | CDC25A (0.78) | NPC1L1USP2RORAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100003711-A1 | Methods to identify therapeutic agents | THE SCRIPPS RESEARCH INSTITUTE (US) | 2010-01-07 | — | — | US | disclosed |
| US-20090275064-A1 | Methods to identify therapeutic agents | THE SCRIPPS RESEARCH INSTITUTE (US) | 2009-11-05 | — | — | US | disclosed |
| EP-1929313-A2 | METHODS TO IDENTIFY THERAPEUTIC AGENTS | The Scripps Research Institute (US) | 2008-06-11 | — | — | EP | disclosed |
| US-20070059242-A1 | METHODS TO IDENTIFY THERAPEUTIC AGENTS | SCRIPPS RESEARCH INSTITUTE, THE | 2007-03-15 | — | — | US | disclosed |
| WO-2007022089-A2 | METHODS TO IDENTIFY THERAPEUTIC AGENTS USEFUL FOR TREATING AND PREVENTING ATHEROSCLEROSIS BY COUNTERACTING THE EFFECT OF CHOLESTEROL OZONATION PRODUCTS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2007-02-22 | — | — | WO | disclosed |
| US-20060217359-A1 | Therapeutic procedures | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2006-09-28 | — | — | US | disclosed |
| US-20060210554-A1 | Detection of cholesterol ozonation products | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2006-09-21 | — | — | US | disclosed |
| EP-1670812-A2 | OZONATION PRODUCTS OF CHOLESTEROL FOR THE TREATMENT AND PREVENTION OF ATHEROSCLEROSIS AND/OR CARDIOVASCULAR DISEASES | The Scripps Research Institute (US) | 2006-06-21 | — | — | EP | disclosed |
| EP-1668026-A1 | DETECTION OF CHOLESTEROL OZONATION PRODUCTS | The Scripps Research Institute (US) | 2006-06-14 | — | — | EP | disclosed |
| US-20050085557-A1 | Oxidation of cholesterol in atherosclerosis plaque; cytotoxic | SCRIPPS RESEARCH INSTITUTE, THE | 2005-04-21 | — | — | US | disclosed |
| US-20050085556-A1 | Detection of cholesterol ozonation products | SCRIPPS RESEARCH INSTITUTE, THE | 2005-04-21 | — | — | US | disclosed |
| WO-2005023830-A2 | OZONATION PRODUCTS OF CHOLESTEROL FOR THE TREATMENT AND PREVENTION OF ATHEROSCLEROSIS AND/OR CARDIOVASCULAR DISEASES | THE SCRIPPS RESEARCH INSTITUTE (US) | 2005-03-17 | — | — | WO | disclosed |
| WO-2005023831-A1 | DETECTION OF CHOLESTEROL OZONATION PRODUCTS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2005-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070059242-A1 | METHODS TO IDENTIFY THERAPEUTIC AGENTS | MSR1, SCARB1, LDLR | NPC1L1 161/4885USP2 3904/4885RORA 97/4885 |
| US-20050085556-A1 | Detection of cholesterol ozonation products | APOB, CETP, PCSK9 | NPC1L1 24/4885USP2 1571/4885RORA 653/4885 |
| US-20050085557-A1 | Oxidation of cholesterol in atherosclerosis plaque; cytotoxic | APOB, LDLR, CETP | NPC1L1 14/4885USP2 2775/4885RORA 690/4885 |
| US-20060217359-A1 | Therapeutic procedures | APOB, LIPA, CETP | NPC1L1 22/4885USP2 2846/4885RORA 1029/4885 |
| US-20090275064-A1 | Methods to identify therapeutic agents | MSR1, SCARB1, LDLR | NPC1L1 161/4885USP2 3911/4885RORA 102/4885 |
| US-20060210554-A1 | Detection of cholesterol ozonation products | APOB, CETP, PCSK9 | NPC1L1 24/4885USP2 1571/4885RORA 653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.